trending Market Intelligence /marketintelligence/en/news-insights/trending/5bwdue5kyy_diadgvcpamw2 content esgSubNav
In This List

Israel's DreaMed gets US FDA approval to market diabetes management software

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Israel's DreaMed gets US FDA approval to market diabetes management software

Privately held DreaMed Diabetes, Ltd. said the U.S Food and Drug Administration approved for marketing its artificial intelligence-based software Advisor Pro for the management of diabetes.

The Israeli company said the cloud-based digital solution is used to assist healthcare providers in the management of people with type 1 diabetes who use insulin pumps and continuous glucose monitoring.

The software generates insulin delivery recommendations by analyzing information from glucose monitoring systems and insulin pumps.

DreaMed said Advisor Pro received the EU's CE mark designation for assisting healthcare professionals in the management of type 1 diabetes.